Dentsply Sirona Beats Q2 Adjusted EPS Consensus at $0.52 and Reaffirms FY26 Outlook
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-09. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Stronger operational cost control offsets top-line declines, protecting Dentsply Sirona operating cash flow and reaffirming full-year EPS guidance.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factDentsply Sirona reported Q2 adjusted EPS of $0.52 compared to the consensus estimate of $0.36. |
| What else was confirmed? | Reported factConsolidated revenue fell 4.1% year-over-year. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for XRAY yet — this is the next research task. |
| What would change the assessment? | UnknownDental consumable sales volumes — Track post-earnings distributor commentary on elective dental procedural volumes. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Dentsply Sirona reported Q2 adjusted EPS of $0.52 compared to the consensus estimate of $0.36.
- · Consolidated revenue fell 4.1% year-over-year.
- · Wellspect Healthcare segment revenue grew 7.1%.
- · The company reaffirmed full-year 2026 sales guidance of $3.5B to $3.6B and adjusted EPS of $1.40 to $1.50.
Public research record
Research framework · page evidenceCompleted event assessment
earnings beat and FY2026 guidance reaffirmation
| Type | Claim | Scope |
|---|---|---|
| Assumption | Dentsply Sirona reported Q2 adjusted EPS of $0.52 compared to the consensus estimate of $0.36. | 2026-09-09 |
| Interpretation | earnings beat and FY2026 guidance reaffirmation | XRAY |
Countercase, invalidators, and sources
Cost efficiencies sustain margin outperformance into H2 2026, pushing EPS toward upper end of $1.50 guidance.
- · Dental consumable sales volumes — Track post-earnings distributor commentary on elective dental procedural volumes.
- XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure · 2026-09-08
What remains unresolved
- Base path
- Revenues track within the $3.5B to $3.6B corridor as dental consumable volumes stabilize.
- Adverse path
- Further organic top-line contraction erodes gross margins below full-year forecast assumptions.
- Supportive path
- Cost efficiencies sustain margin outperformance into H2 2026, pushing EPS toward upper end of $1.50 guidance.
- · Dental consumable sales volumes — Track post-earnings distributor commentary on elective dental procedural volumes.this week
Evidence
- XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure2026-09-08
“DENTSPLY SIRONA (XRAY) exceeded Q2 earnings and revenue estimates with adjusted EPS of 52 cents versus 36 cents consensus, though revenues fell 4.1% year-over-year. The company maintained full-year 2026 guidance...”
Supports: Q2 adjusted EPS was $0.52 vs $0.36 consensus; revenue fell 4.1%; 2026 guidance maintained at $3.5-3.6B sales and $1.40-1.50 EPS.